# China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2025 Version)

PMC · DOI: 10.3779/j.issn.1009-3419.2025.102.43 · Chinese Journal of Lung Cancer · 2025-12-20

## TL;DR

This paper revises the 2025 Chinese lung cancer screening guidelines using low-dose CT to improve efficiency and reduce risks.

## Contribution

The paper updates the LDCT screening guidelines with new criteria for high-risk populations and nodule management.

## Key findings

- The revised guidelines clarify high-risk population criteria, including occupational exposure duration.
- Nodule size measurement now uses average diameter, and follow-up intervals have been adjusted.
- Informed consent and shared decision-making are emphasized throughout the screening process.

## Abstract

肺癌是导致中国癌症死亡的首要原因。通过优化肺癌筛查策略，提高筛查效率，减少相关危害已成为当前肺癌筛查的研究热点和方向。本文的目的是对2023年中国肺癌低剂量计算机断层扫描（low-dose computed tomography, LDCT）筛查指南进行修订。由国家卫健委指定的中国肺癌早诊早治专家组专家及部分中国西部肺癌研究协作中心专家，共同参与了2025年版中国肺癌LDCT筛查指南的修订工作。专家组根据近年来国内外LDCT肺癌筛 查进展，结合我国肺癌流行病学特征，共同修订了本肺癌筛查指南。本指南对以下内容进行了修订：（1）高危人 群定义中明确了职业暴露年限，另外，如果在年度筛查中发现受检者身体状况无法耐受可能的肺癌切除手术，或罹患其他严重威胁生命的疾病，则建议停止LDCT筛查；（2）更新了结节大小的测量方法，将平均直径作为结节大小的衡量指标；（3）结节管理中，将基线筛查中实性结节或部分实性结节实性成分的平均直径阳性阈值提高至6 mm，并将实性结节或部分实性的阳性结节复查时间由6个月调整为3-6个月；（4）建议将知情同意和共同决策贯穿于高危人群选择、筛查间隔和结节管理环节。本次修订进一步明确和优化了高危人群选择及结节管理，并在对肺癌筛查获益和危害充分权衡基础上，强调了知情同意和共同决策的重要性。本次修订将使得LDCT筛查指南更适应我国国情，并提升了我国肺癌筛查的规范性与适用性。

## Full-text entities

- **Diseases:** Lung Cancer (MESH:D008175), cancer (MESH:D009369), nodule (MESH:D016606), Lung (MESH:D008171)
- **Chemicals:** lung carcinogens (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12972581/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12972581/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12972581/full.md

---
Source: https://tomesphere.com/paper/PMC12972581